Contact Lenses for Near-sightedness
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to understand how a new type of contact lens affects blood flow in the eye and comfort for individuals with nearsightedness. Participants will wear two types of lenses: an experimental lens with a special design called the Myopic Defocus Soft Lens Design (MDSL) and a regular lens already available on the market. The study will assess changes in the eye and gather feedback on comfort and vision after participants wear each lens for a week. Ideal candidates are healthy young adults with nearsightedness between -0.50 and -4.00D, no significant astigmatism, and good vision in both eyes. As an unphased trial, this study provides a unique opportunity to contribute to innovative research that could enhance vision care for many.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot participate if you've recently taken medications affecting blood pressure or if you use topical eye medications.
What prior data suggests that these contact lenses are safe for near-sighted individuals?
Research has shown that contact lenses designed to reduce nearsightedness, such as the Myopic Defocus Soft Lens (MDSL), have generally been well-received in past studies. These studies, mostly involving children, indicate that such lenses can effectively slow the progression of nearsightedness. Importantly, no major safety issues were reported during their use.
The Single Vision Soft Lens (SVSL) is already popular in places like the US and Canada, indicating its safety and effectiveness for correcting vision without major safety concerns.
In summary, both types of lenses appear safe based on previous research and their market use. However, individual experiences may vary, so it's important to consider any specific sensitivities or conditions.12345Why are researchers excited about this trial?
Researchers are excited about the Myopic Defocus Soft Lens Design (MDSL) because it introduces a unique approach to managing near-sightedness. Unlike standard single-vision lenses that solely correct distance vision, MDSL incorporates a special myopic defocus zone. This design includes a central zone for clear distance vision, surrounded by a convex area that intentionally creates a defocus effect. This feature is believed to help slow down the progression of myopia by altering the way light is focused on the retina. Such an innovative approach could offer a dual benefit: correcting vision while potentially managing the condition's advancement.
What evidence suggests that this trial's contact lenses could be effective for near-sightedness?
Research shows that special soft contact lenses, called myopic defocus soft lenses (MDSL), can help slow down nearsightedness, especially in children and young teens. Studies have found that wearing these lenses daily can significantly reduce the eye's elongation, a main cause of worsening nearsightedness. For example, one study found that using MDSL led to a 25% decrease in the progression of nearsightedness. While most research focuses on children, these results suggest that MDSL might also help young adults by managing changes in their eyes. In this trial, participants will be assigned to either the MDSL arm or the single vision soft lens design (SVSL) arm. Thus, MDSL could be a promising way to control nearsightedness.12367
Who Is on the Research Team?
Langis Michaud, OD MS
Principal Investigator
Universite de Montreal
Are You a Good Fit for This Trial?
This trial is for healthy young adults aged 18-35 with mild to moderate near-sightedness (myopia between -1.00D and -4.00D). Participants must be willing to wear two types of soft contact lenses, each for one week, and undergo eye scans.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline Measurement
Initial measurements of deep and superficial plexus blood vessel density and choroidal thickness are taken with an angiographic optical coherence tomograph (OCT-A Triton, Topcon USA).
Treatment
Participants wear each type of contact lens (MDSL and SVSL) for one week each, in a random order. Measurements are repeated at the end of each week.
Follow-up
Participants are monitored for changes in retinal blood flow and choroidal thickness after wearing the contact lenses.
What Are the Treatments Tested in This Trial?
Interventions
- Myopic defocus soft lens design (MDSL)
- Single vision soft lens design (SVSL)
Trial Overview
The study tests if a myopic defocus soft lens design (MDSL) affects retinal blood flow and choroidal thickness compared to standard single vision lenses (SVSL). It includes wearing both lens types, eye scanning with OCT technology, and completing comfort questionnaires.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Active Control
This arm involves the wear of a daily disposable soft contact lens (nesofilcon A) designed with a myopic defocus zone. This is a 14.2mm total diameter lens with a 4.2mm central zone for distance vision correction. This is followed by an abrupt transition zone of 1.2mm with no optical power. Then a higher convex power zone covers the surface to the edge of the optical zone (8mm). The rest of the lens (up to 14.2 mmOAD) supports the lens on the eye surface and has no power nor refractive effect. The power of the add area is calibrated to the central power to achieve a net add power of +5D. For example: -1.00D central power is surrounded by a +6D convex area; -2D is surrounded by a +7D area, and so on.)
This arm involves the wear of a daily disposable soft contact lens (nesofilcon A) designed as a regular optical device to compensate for refractive error. In the case of this study, this lens will be made available from -1.00D to -4.00D. This lens is already in regular use in the US (K113703) and Canadian markets. Its design includes a central optical zone of 8mm that is powered to correct distance vision. The rest of the lens is supported on the ocular surface and has no power.
Myopic defocus soft lens design (MDSL) is already approved in European Union, United States for the following indications:
- Myopia control
- Retardation of myopia progression
- Myopia control
- Retardation of myopia progression
Find a Clinic Near You
Who Is Running the Clinical Trial?
Université de Montréal
Lead Sponsor
Bausch & Lomb Incorporated
Industry Sponsor
Dr. Christina Ackermann
Bausch & Lomb Incorporated
Chief Medical Officer since 2023
MD from Harvard Medical School
Brent Saunders
Bausch & Lomb Incorporated
Chief Executive Officer since 2023
BA from the University of Pittsburgh, JD and MBA from Temple University
Published Research Related to This Trial
Citations
Defocus Incorporated Soft Contact (DISC) lens slows ...
The daily wearing of DISC lens significantly slowed myopia progression and axial elongation in Hong Kong schoolchildren.
One-Year Myopia Control Efficacy of a New Defocus ...
The primary outcome was the 1-year change in SER from baseline to 12 months. Secondary outcomes included changes in axial length (AL), ...
Real–world outcomes on myopia management efficacy of ...
DSDO showed more stable myopia control effect comparing to DIMS, especially in groups of SER≤–2.0D sub–groups and older patients. DSDO showed initial potential ...
Effect of daily disposable Defocus Incorporated Soft ...
The study has shown that DISC lens use resulted in a significant myopia control effect in children and young adolescents aged 7–11 years. This ...
Myopia control using a modified optical defocus soft ...
Defocus Incorporated Soft Contact (DISC) lenses with +2.50 D myopic defocus reduced myopia progression by 25% in a previous randomised ...
Real-world outcomes of Defocus Incorporated Multiple ...
The study demonstrated that DIMS lenses could retard axial elongation, with the effect sustained with increased duration of lens wear.
Long-term myopia control effect and safety in children ...
Defocus incorporated soft contact (DISC) lens slows myopia progression in Hong Kong Chinese schoolchildren: A 2-year randomized clinical trial.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.